The verdict
Our read at a glance.
Whether atosiban's role is understood as a generally well-tolerated way to delay threatened preterm labor for a short window, rather than a proven way to improve babies' outcomes, and whether its mixed regulatory history is kept in view.
- The signal
- Trials show atosiban can delay threatened preterm labor and is generally easier to tolerate than older tocolytics like beta-agonists, with fewer heart-related side effects. But like other tocolytics, clear evidence that it improves the baby's outcomes is limited; its main value is buying a short window.
- The unknown
- Whether delaying labor with atosiban actually improves how babies do, beyond the roughly 48-hour window used to give steroids and arrange transfer, and how it compares with other tocolytics.
- Our read
- A well-tolerated way to briefly delay threatened preterm labor that blocks the oxytocin receptor, making it the mirror image of oxytocin and carbetocin. Its honest value is buying about 48 hours for steroids and transfer, not a proven improvement in how babies ultimately do, and it is approved in Europe but not by the US FDA, partly over an early-gestation safety signal.
The mechanism
How it works.
Labor contractions are driven in part by the hormone oxytocin acting on oxytocin receptors in the muscle of the uterus. Atosiban is a modified oxytocin peptide that binds those same receptors but does not switch them on; by occupying them it blocks oxytocin (and the related hormone vasopressin) from triggering contractions, so the uterus relaxes and early labor can be slowed. It is the opposite of oxytocin and its long-acting analog carbetocin, which activate the receptor to make the uterus contract. The goal is usually to delay birth long enough to give steroids that speed the baby's lung development and to move the mother to a unit equipped for a premature delivery.
Safety & regulatory boundary
The consequential part.
Atosiban is generally better tolerated than beta-agonist tocolytics. It is approved in the European Union and many other countries but is not FDA-approved in the United States; a US review raised concern about more infant deaths in a subgroup of very early (under about 28 weeks) pregnancies in one placebo-controlled trial, which weighs on its use at the earliest gestational ages. It is a hospital drug for threatened preterm labor and is the opposite of oxytocin and carbetocin, blocking rather than activating the oxytocin receptor.
What's next
What we're watching.
Better data on whether tocolysis with atosiban improves neonatal outcomes, its role at the earliest gestational ages, and head-to-head comparisons with nifedipine and other tocolytics.
Context
Why this is discussed.
Atosiban blocks the oxytocin receptor to calm a uterus going into early labor. It is the mirror image of oxytocin and carbetocin, which switch that receptor on, and it is used to try to delay preterm birth, mainly to buy time for steroids that help the baby's lungs.
The evidence base
14 cited references.
Registered trials4
ClinicalTrials.gov · NA · RECRUITING · 2025-12-06
ClinicalTrials.gov · NA · COMPLETED · 2018-01-03
ClinicalTrials.gov · PHASE4 · COMPLETED · 2017-12-01
ClinicalTrials.gov · COMPLETED · 2017-10-01
Indexed literature (PubMed)10
van der Windt LI et al. · Lancet · 2025
Ali AA et al. · Int J Gynaecol Obstet · 2019
Shubert PJ · Clin Obstet Gynecol · 1995
Wang R et al. · Front Endocrinol (Lausanne) · 2023
Thornton JG · BJOG · 2005
Chandraharan E et al. · Curr Opin Obstet Gynecol · 2005
Riemma G et al. · Eur J Obstet Gynecol Reprod Biol · 2021
Haas DM · BMJ Clin Evid · 2011
Haas DM et al. · BMJ · 2012
Haas DM · BMJ Clin Evid · 2008
Keep reading